Evidence map›Paper›PMID 24744854›Full record

ArticlePhysiological reports2013

Sphingosine-1-phosphate acts as a key molecule in the direct mediation of renal fibrosis.

Shunji Shiohira, Takumi Yoshida, Hidekazu Sugiura, Miki Nishida, Kosaku Nitta, Ken Tsuchiya

Open access · goldAbstract read
In one paragraph

Article in Physiological reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Sphingolipid signaling in kidney diseases.American journal of physiology. Renal physiology · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Loss of sphingosine kinase 2 protects against cisplatin-induced kidney injury.American journal of physiology. Renal physiology · 2022
    Article
  7. Review
  8. Article
  9. Article
  10. Sphingosine-1-phosphate pathway in renal fibrosis.American journal of physiology. Renal physiology · 2018
    Review
  11. Article
  12. Article
  13. Article
  14. Sphingosine Kinase 2 Deficiency Attenuates Kidney FibrosisJournal of the American Society of Nephrology : JASN · 2017
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shunji ShiohiraDepartment of Medicine IV, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan.
Takumi YoshidaDepartment of Medicine IV, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan ; Yoshida Medical Clinic, Suginami, Tokyo, Japan.
Hidekazu SugiuraDepartment of Medicine IV, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan.
Miki NishidaDepartment of Medicine IV, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan.
Kosaku NittaDepartment of Medicine IV, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan.
Ken TsuchiyaDepartment of Medicine IV, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan.
Tokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The major sphingolipid metabolite, sphingosine-1-phosphate (S1P), has important biological functions. S1P serves as a ligand for a family of five G-protein-coupled receptors with distinct signaling pathways regulating important biological pathways. S1P induces renal fibrosis through an inflammatory pathway. However, its direct fibrosis-inducing effect on the kidney has not been shown. The role of S1P as a direct mediator of renal fibrosis was investigated in normal rat kidney interstitial fibroblast (NRK-49F) cells (in vitro) and kidneys of a unilateral ureteral obstruction (UUO) mouse model (in vivo). To clarify the role of S1P in renal fibrosis, we adopted nude UUO mice with immune response deficits. NRK-49F cells were stimulated with various concentrations of exogenous S1P and FTY720 (a S1P receptor agonist) or N,N-dimethylsphingosine (DMS; a sphingosine kinase inhibitor). C57BL6 and nude UUO mice were pretreated with FTY720, DMS, or saline. Expression levels of alpha-smooth muscle actin (a-SMA), E-cadherin, collagen type 1 (COL1), collagen type 4 (COL4), tissue inhibitor of matrix metalloproteinase-1 (TIMP1), and plasminogen activator inhibitor-1 (PAI1) were examined. S1P stimulated fibrosis in NRK-49F cells and UUO mice. Increased a-SMA, COL1, COL4, TIMP1, and PAI1 and decreased E-cadherin expression levels were observed in both the S1P-stimulated cells and UUO mice. Nude UUO mouse kidneys expressed fibrotic markers. Fibrotic changes were successfully induced in both UUO and nude UUO mice, evident through prominent fibronectin and COL1 staining. These S1P-induced fibrotic changes were suppressed by FTY720 and DMS both in vitro and in vivo. Thus, S1P essentially and directly mediates renal fibrosis.

Indexed as

DMSFTY720renal fibrosissphingosine‐1‐phosphateUUO

Identifiers

PMID24744854
PMCPMC3970738
OpenAlexW2065239075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.